Navigation Links
The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
Date:5/17/2011

BUFFALO, N.Y., May 17, 2011 /PRNewswire/ -- Kinex Pharmaceuticals, LLC announced today that Dr. David Hangauer, who served as the Founding Senior Vice President of Research, will be appointed as Chief Scientific Officer of the Company.  

Dr. Johnson Lau, Chairman and Chief Executive Officer, stated, "David discovered and designed both of our lead compounds, KX01 and KX02. He is the soul of our scientific discovery programs. I have worked together with him for the last 7 years and he is always at his best, both scientifically and from his managing of the scientific team. I am honored that he has accepted the Chief Scientific Officer position and I look forward to working with him to grow Kinex Pharmaceuticals from a scientific perspective."

Dr. Hangauer is a leader in the field of medicinal chemistry.  Following doctoral studies in chemistry at The University at Buffalo, he spent nine years at Merck Sharp and Dohme Research Laboratories where he directed a variety of drug discovery projects and, in addition, was an early pioneer in the area of structure-based drug design.  In 1989, he returned to academia and joined the chemistry faculty at The University at Buffalo where he has had a productive research career that focused initially on developing a new approach to the design of protein kinase inhibitors which led to Mimetica™, the patented technology Kinex Pharmaceuticals licensed from The University at Buffalo and upon which the company was originally based.

Dr. Hangauer's academic research is focused on the energetics of drugs binding to their receptors and has published extensively in this area. He has taught a range of courses to graduate and undergraduate students in medicinal and organic chemistry.  

Dr. Hangauer's expertise has been sought by pharmaceutical and biotechnology companies worldwide, including Lederle /Wyeth-Ayerst Research Laboratories, New Medical Technologies, Sphinx/Eli Lilly Pharmaceuticals Inc., Yuhan Corporation, Periodontix, Inc., ICAgen, Inc., ARPIDA, Scientific Advisory Board & Founding Scientist, Suntory Pharmaceuticals Research Laboratories and Signal Pharmaceuticals, Inc. Most notably he led the chemistry effort at Hypnion, Inc., that resulted in the discovery and development of an insomnia drug.  The Company was sold to Eli Lilly in 2009 for more than $300 million and its major asset was the insomnia drug that was designed and discovered under the leadership of Dr. Hangauer.

Dr. Allen Barnett, President Emeritus, states, "David well deserves this recognition. He is indeed the soul of Kinex Pharmaceuticals' discovery programs. I am delighted to have the opportunity to continue supporting David and his scientific programs and I am confident that he is going to make many more major discoveries in the years to come."

Dr. Rudolf Kwan, Chief Medical Officer, states, "David is a great scientist to work with. He can translate complex scientific questions into simple solutions. He also understands the clinical needs and is helping the clinical team to shape the development programs."

Dr. David Hangauer states, "Kinex Pharmaceuticals has evolved nicely, thanks to all of the members of the management team. I am proud to be part of this innovative team and will continue my efforts to assist the Company in discovering more novel therapies for important unmet medical needs.  Kinex will prosper as a business by focusing our efforts on the discovery and development of novel drugs that provide major benefits to patients, and it is this contribution to humanity that provides the most satisfaction for scientists such as me."

About Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica™ and Opal™ to discover and develop novel drugs for oncology and immune-modulatory diseases.  More information of Kinex Pharmaceuticals can be found at  www.kinexpharma.com

Kinex Pharmaceuticals, LLC – Caution Regarding Forward-looking Information

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Kinex Pharmaceuticals cautions investors that any forward-looking statements or projections made by Kinex Pharmaceuticals, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

Kinex Inquiries:

Lyn M. Dyster, Ph.D.
VP, Operations
Kinex Pharmaceuticals
New York Center of Excellence
701 Ellicott Street
Buffalo, NY 14203
USA
Tel: 716.898.8626
E-mail: ldyster@kinexpharma.com


'/>"/>
SOURCE Kinex Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
2. HYCOR Expands Board of Directors to Support Growth in Key Areas
3. Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate
4. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer
5. TriReme Medical Lines Up Asian Strategy With Key Appointment of New Board Members
6. Qforma Appoints New Member to Board of Directors
7. Abaxis Appoints Vernon Altman to Board of Directors
8. TeleTrackings Patient Flow Dashboard XT™ Stops Operational Problems Before They Start
9. Hospira Board Authorizes $1 Billion Share Repurchase Program
10. Thomas Mac Mahon Joins SynapDx Corporations Board of Directors
11. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):